Objective To investigate the clinical efficacy of avatrombopag and recombinant human thrombopoietin(rh-TPO)in the treatment of severe thrombocytopenia after liver transplantation.Methods Clinical data of 81 patients with severe thrombocyto-penia after liver transplantation from February 2016 to March 2023 in the First Affiliated Hospital of Anhui Medical University were ret-rospectively analyzed.Of 81 patients,38 patients receiving avatrombopag treatment were allocated into the avatrombopag group,and 43 patients receiving rhTPO treatment were allocated into the rhTPO group.The main parameters measured were platelets changes,thera-peutic response rate,postoperative outcomes,changes in liver and kidney functions,and short-term survival rates.Results The platelet counts of patients in the avatrombopag group were significantly higher than those of patients in the rhTPO group on days 3,5,7,10,and 15 after treatment(P＞0.05),and there was no difference on day 30(P＜0.05).Patients in the avatrombopag group showed a significantly higher therapeutic response rate than that in the rhTPO group(84.2％VS 58.1％,P＜0.05),and the inci-dence of postoperative infection was significantly lower in the avatrombopag group.There were no significant differences in the inci-dence of bleeding and thrombosis and liver and kidney functions between the two groups during treatment period(P＞0.05).Conclu-sion Both avatrombopag and rhTPO could elevate platelet levels in patients with severe thrombocytopenia after liver transplantation,and avatrombopag showed better clinical efficacy than rhTPO.
关键词
阿伐曲泊帕/重组人血小板生成素/肝移植/血小板减少
Key words
avatrombopag/recombinant human thrombopoietin,liver transplantation/thrombocytopenia
维普
万方数据